Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$715 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.2
Industry P/E
--
EV/EBITDA
-1.1
Div. Yield
0 %
Debt to Equity
0.5
Book Value
$0.6
EPS
$-1
Face value
--
Shares outstanding
266,866,897
CFO
$-1,045.16 Mln
EBITDA
$-1,317.27 Mln
Net Profit
$-1,303.24 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sana Biotechnology (SANA)
| -21.4 | -24.0 | -21.4 | 113.3 | -0.7 | -36.9 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Sana Biotechnology (SANA)
| 149.7 | -59.7 | 3.3 | -74.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sana Biotechnology (SANA)
|
3.2 | 715.2 | 0.0 | -244.2 | -- | -118.7 | -- | 5.2 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including... type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. Address: 188 East Blaine Street, Seattle, WA, United States, 98102 Read more
President, CEO & Director
Dr. Steven D. Harr M.D.
President, CEO & Director
Dr. Steven D. Harr M.D.
Headquarters
Seattle, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sana Biotechnology Inc (SANA) is $3.20 (NASDAQ) as of 02-Apr-2026 19:52 EDT. Sana Biotechnology Inc (SANA) has given a return of -0.72% in the last 3 years.
Since, TTM earnings of Sana Biotechnology Inc (SANA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.22
|
6.40
|
|
2024
|
-1.41
|
1.50
|
|
2023
|
-2.81
|
2.77
|
|
2022
|
-2.79
|
1.49
|
|
2021
|
-7.47
|
3.53
|
The 52-week high and low of Sana Biotechnology Inc (SANA) are Rs 6.55 and Rs 1.26 as of 04-Apr-2026.
Sana Biotechnology Inc (SANA) has a market capitalisation of $ 715 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sana Biotechnology Inc (SANA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.15
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.